Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Aagami Corporate Presentation

1,238 views

Published on

Aagami, Inc., is a life science consulting firm which offers
• Strategic Consulting (including Business Development support in regions where you are unable to reach out due to bandwidth)
• Technology Licensing
• Market Research Services
for Global Biotech, Pharmaceutical, Medical Technology and Consumer Health products companies

In Brief, Aagami Brings:
• Global Deal experience
• Extensive ‘C’ level network
• Deep Understanding of business and socio-cultural differences in ways of working
• 250+ years combined experience
• Focus on client needs, objectives, and success

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Aagami Corporate Presentation

  1. 1. Strategic Consulting |Technology Licensing |Market Intelligence → Realizing Possibilities, Together ← Aagami , Inc. | 2135 City Gate Lane, Suite 300, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com January 2018 Meet us at
  2. 2. Aagami One Page Factsheet 60+ Clients 125+ Assignments Large ‘C’ level network 20+ deals Multi- geographic presence 250+yrs Global Experience Client Success – most important US$ 500+MM X-Border deals and Investments Dinesh Jain Elizabeth Song Michael RosenLinda Pullan 2
  3. 3. 3 Aagami, Inc. A life sciences consulting firm offering  Strategic Consulting  Technology Licensing  Market Intelligence Pharma Biotech Medical Devices Consumer Healthcare CROs/CDMOs Research Institutes & Universities For Global
  4. 4. 4 Your Needs, we Serve In-Licensing Out-Licensing Partnership/ Co-Development Funding/Investment Mergers & Acquisitions Market Entry/Development Strategy Finding the Right Partners • JV and/or Distributors/ Contract Sales/Marketing/Contract Manufacturing, CRO and CRAMS providers
  5. 5. Certain challenges Clients face 5 Considerable time spent with immense value of your cost per hour Opportunity Cost Uncertainty on Results Understanding dynamics of all markets is difficult Limited connections in Target geographies
  6. 6. Deep Understanding of business and socio-cultural differences in ways of working of various countries Extensive ‘C’ level network Global Deal experience Aagami Partners bring combined experience of 250+ years Augmenting your bandwidth to save time, effort & cost Solutions Aagami brings
  7. 7. 7 Many companies such as yours have benefitted from our services  Licensing and Co-Development partnership for Novel Protein Therapeutic Platform of a German company; Deals done with 2 Major Pharma.  Investment for development of therapies and vaccines of a oncology focused Louisiana Biotech Company. Facilitated Listing on OTC Markets using reverse merger resulting in Line of Credit (US$ 10mn).  Licensing of a dermal delivery system of an Australian company, applicable to both pharmaceutical and personal care products. Licensing Deals signed with 3 companies; Product launched with one; A few more deals in discussion.  Finding customers for Peptides API for a EU conglomerate. Orders received from 8 companies.  Out-Licensing & Distribution partnerships for an Ophthalmic Medical Device company. Signed with a major Pharma Company.  Creation and management of MSDS for a Fortune 100 Chemical company from Midwest US by striking alliance with the right partner in India. 85% Cost reduction was achieved within 6 months of starting operation. Few Examples of successes brought out to our clients: (Also see Case Studies for more details)
  8. 8. 8 Sample list of Clients whom Aagami has served USA Batu Biologics CA New Heaven Pharma CT Advangene IL Loyola Univ. Chicago IL OncBioMune LA Dow Chemicals MI ScyFIX MN Penwest Corp. NY DesignMedix OR DisperSol TX International Avixgen South Korea PeptiSyntha Belgium DelMar Pharma Canada SiSaf UK Pieris Germany Getinge Group Sweden Opsona Ireland Toppan Japan Temple Nederland Phosphagenics Australia Completed 125+ assignments for 60+ clients since 2003
  9. 9. 9 Strategy Segment IN Licensing OUT Licensing M & A Partnership Co-Development Regulatory Market Research & Entry Supply Chain & Distribution BD Pharmaceuticals Biotechnology CRO & CRAMS Delivery Technology Diagnostics Consumer Health Products Nutraceuticals/ Cosmeceuticals Medical Device Labware Supported all Segments and Strategies The colored boxes represent our experience in that Sector and assignment completed in Strategic area
  10. 10. 10 The tested and proven Approach> For your Success Setup • Understand and capture important details about the asset/technology • Prepare ‘Elevator Pitch’ (EP) customized to specific business culture • Identify relevant companies from our database and resources Prospect • Broadcast EP to Relevant Companies • Follow-up with phone calls and emails • Coordinate CDAs with interested Companies • Supply further info through emails • Organize conference calls for clarifications Finalize • Organize Road show • Manage appointments with right executives • Coordinate the logistics of the road show • Advise on structuring the deal • Support in negotiations (most critical) For clients on the sell side. Approach is customized as per nature of assignment
  11. 11. 11 Engagement Model  Dedicated Teamwork (60-80 Hours/month/geography)  Small monthly ‘commitment’ fee for first 6 months  Success bonus % of deal value according to Lehman formula elaborated in consulting agreement draft  The gap between the commitment fee and a retainer, is our investment.  For Aagami to Succeed our prime focus is YOUR SUCCESS
  12. 12. 12 Dinesh Jain, MBA – Founder CEO • A business leader in Science and technology industry since 1984 with global experience in starting and managing several technology companies. Has held positions of CEO, President, Vice President. Is a prolific entrepreneur. Has executed several dozen international deals across 4 continents. He is a regular speaker in International conference son Life Sciences Business with India, and also on board of several consulting and research companies Dr. Mahendra Shah, Ph D – Scientific & Business • A veteran Scientific leader in Bio-Pharmaceutical field since 1968 . After his PhD, he has worked with some of the top notch companies like Bristol, Squibb, Schering, Lyphomed, Fujisawa, EJ Financials, First Horizon, NextWave. Mahendra is an active Investor in BioPharmaceutical field and is on the Board of several companies across the country. Michael S. Rosen, MBA - Business • A Senior executive and entrepreneur working globally since 1974. Managed 3 multinational pharma and agro- science companies working in Europe, Latin America, Japan, Canada, Asia and Israel. CEO experience starting and growing several biotech and medical device companies in the U.S. and Europe, raising more than $50 million in equity and taking 1 company public. Economic development expertise creating and expanding vibrant science parks and life-science ecosystems as public-private partnerships Aagami Leadership Team 1 of 3
  13. 13. 13 Aagami Leadership Team 2 of 3 Dr. Shridhar Andurkar, Ph D – Scientific • Chair and Associate Professor of Pharmaceutical sciences at Midwestern University, Chicago College of Pharmacy, is a Ph D from Auburn University in Medicinal Chemistry, Conducted postdoctoral research at the University of Houston. Dr. Andurkar has published numerous papers and made several presentations in this field. He holds a US patent in the area of anticonvulsant drugs and is on the advisory boards of several companies. Nancy Chew - Regulatory • A serial entrepreneur, veteran business leader, biochemist and Pharmacologist by education, Regulatory expert, Several top honors & award winner and Advisor to numerous Life Sciences companies. Nancy's accomplishments and achievements of over 39 years would take several pages to detail. Dr. Aman Ahuja, M.D., F.P.M., F.R.C.A. – Medical • A specialist pain medicine physician and consultant at the North Queensland, Australia. MD Anaesthesia from India, Fellow of Royal College of Anaesthetists, Ireland, Masters in Pain Medicine from UK, Fellow of Tess Cramond Multidisciplinary Pain Centre, Australia; Dr. Ahuja has focus on clinical practice, research and advancing rational therapies for a diverse range of conditions. His current interests include studying the expanding role of radiofrequency in field of Pain Medicine. Dr. Ahuja uses a compassionate and multidisciplinary approach in his well known practice as a Pain Specialist and Anesthetist.
  14. 14. 14 Godwyn Francis – Vice President • Godwyn brings 15 years of experience with companies like Accenture, Prudential, Tata, and other firms in management consulting. At Aagami, Godwyn leads business development and growth efforts for profitable new and existing business. He also lends his support and oversight to research and consulting assignments for global clients. He has worked each year on multiple term sheets and contributed to signing deals worth tens of millions of dollars. Linda Pullan, Ph D– Business and Science • Linda has over25 years of pharmaceutical and biotech experience in research and licensing, business development, R&D and consulting. She has worked for AstraZeneca, Amgen, Kosan Biosciences and now consulting for a decade, helping companies with all aspects of partnering. Linda has an In-depth understanding and proven success in drug development, evaluation, valuation and negotiation for strategic alliances and licensing deals. Linda has authored 66 scientific literature publications. She has also been honored as an Advisor, Reviewer, Lecturer and Speaker. Elizabeth Song, Ph D– Business and Science • Elizabeth Song, Ph.D., is a Global Senior Executive, with over 25 years of progressive experiences in business and corporate development in established, emerging and start-up biotechnology companies. She has 15 years of experience in operational and logistical management for clinical trials in the US, Europe and Asia including Korea. Dr. Song’s presence is immensely valuable to Aagami in enhancing its business portfolio with her experience and contacts in industry across the world, especially in South Korea. Aagami Leadership Team 3 of 3
  15. 15. 15 Head Office Aagami, Inc. 2135 City Gate Lane Suite 300 Naperville, IL 60653, USA P: +1-630-364-1837 Dinesh Jain Email: dinesh@aagami.com M: +1 630-853-3520 www.aagami.com CONTACT
  16. 16. MARKET INTELLIGENCE through Business & Market Research
  17. 17. Offerings in Market/ Business Research Competitive Landscape Assessments Analysis of Portfolio and Opportunities identification Price Discovery Research Due Diligence IP and Regulatory Research Financial Modeling, NPV valuations New Market Entry strategy Market development strategy 17
  18. 18. Research Methodology Study/ Research •Primary •Interviews with different stakeholders in the Value chain including opinion leaders, vendors and customers •Proceedings of Industry events, press conferences and workshops •Surveys /studies •Secondary •Company websites, social media, blogs, forums and groups •Business directories and databases •Online and offline libraries and government data •Economic and Demographic information, Census •Case studies, Reference Customers, vendors, and associations Analysis •Qualitative •Policy and Regulatory environment •Competitive Landscape Assessment (CLA) •Business Analysis, Industry Analysis •Trends & Drivers, •Challenges and Risks •Quantitative •Market Sizing, Segmentation and Forecasting •Market share and Opportunity Analysis Reporting •Deliverables •Whitepapers •Industry Reports •Investment Models •Trend Reports •Tracking Reports •Competitive Report •Price Discovery Report •Corporate Profiles •Forecasts •Guesstimates •NPV Valuation •Client Presentation and clarifications on client questions Assess, Analyze, Derive, Synthesize, Report 18
  19. 19. SELECT CASE STUDIES  Strategic Consulting  Market Intelligence & Valuations Lifesciences Catalyst 19
  20. 20. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Facilitating investment for development of targeted therapies and therapeutic vaccines • Investments and partnering to further develop its technologies and pipeline. 20 Louisiana based biotechnology company specializing in innovative cancer treatments • Aagami scanned the global market, identified right investors/ partners, and took them to 50 + companies. • With focused efforts 10+ companies had post CDA level scientific and clinical discussions. • Aagami kept facilitating and persevering, 3 companies moved to term sheet level discussions. • Finally Aagami found a right partner to facilitate reverse merger with a OTC Markets listed company. • This is enabling access to large sums of funds to develop clinical stage programs. • Listing on OTC Markets by a reverse merger • Financial resources to enable development of existing pipeline and technologies
  21. 21. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Establishing Partnerships for Development and Commercialisation of Novel Class of Protein Drugs • Innovator partners in India to collaborate on a new class of proteins - Anticalins® to develop various programs in Oncology and Ophthalmology. 21 German Biotech company making safer, effective and differentiated Novel drugs • Aagami identified right partners, and took them to 7 interested companies for Anticalins® • With focused efforts 3 companies moved to term sheet level discussions. Aagami kept facilitating and persevering. 2 companies remained for final negotiations. • Aagami maintained its spirits and perseverance knowing Indian ways of working; even when client was ready to give up as per Western ways. • Finally co development partnership happened in next few months with one company in Oncology. • Second company took more time and couple of visits before signing co-development deal for ophthalmic therapy. • Client signed co-development deals with 2 companies in Oct and Dec 2013 respectively • Right companies, right advice, structure, perseverance and commitment were the key success factor. in making it happen. • Aagami proved highly influential in negotiations for finalization of the deals due to deep experience in business culture nuances of India. • It brought repeat and referral business to Aagami.
  22. 22. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Technology Out-licensing of Transdermal Drug Delivery Technology with 3 Indian Companies across 4 deals  To Out-License TPM® Technology and Co-Develop in clinic products using proprietary Delivery technology and market such products in India and possibly larger region. 22 TPM® Technology and Products Company from Australia  Aagami scanned numerous companies and got 10 relevant companies interested.  Discussion with 8 companies progressed.  Took client to India 3 times for term sheet level meetings and deal signing.  Facilitated entire evaluation and deal structuring process  Aagami made sure testing and other protocols were honoured before deal was made.  During the process Aagami ensured clear understanding despite socio cultural differences in styles of working.  Deals with 3 global companies of India –The first deal was struck for diclofenac topical gel formulation containing TPM platform. The Indian partner not only launched their own product but also out licensed to a major western pharma. Expanded to 16 geographies worldwide in 2016. –The second alliance was struck for use in Skin Whitening and under eye cream. –Third deal - Aagami was able to facilitate a new business model with this prospect, who using client technology increased bio availability as well as stability of a specific antibiotic.
  23. 23. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Reducing cost of creation and management of MSDS Cost reduction for customized MSDS for various countries with unique regulations for thousands of chemicals it produces. 23 Fortune 100 Chemical company from Midwest US • Client is in Chemicals business for over 100 years across 150 countries and needed to create 1000s of MSDS every month. • This had become very expensive due to complexities and different regulatory needs of various countries . • Aagami analysed the situation and suggested offloading such processes to Indian companies • Aagami scanned though its database and network to identify the right partners. • Performed due diligence on the shortlisted agencies and facilitated discussions and influenced negotiations and deal structuring • Aagami helped strike alliance with the right partner in India. • 85% Cost reduction was achieved within 6 months of starting operation • The client continues to employ Global Delivery Model for MSDS creation and management
  24. 24. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Study of Market Potential and Prospective Partners in India for hand-held qPCR Diagnostic Device • Innovation center wanted to study the market potential in India for their innovative mobile, lightweight molecular diagnostic technology and device. • On Aagami’s suggestion, client agreed to include regulatory overview and potential partners in the study. 24 Innovation Center of a New Zealand University focused on Health Sciences • Aagami involved a team of a senior and a junior researcher to conduct secondary and primary research to assess and collect market data. • Identified Competitors and their product ranges and also did a brief comparison analysis. • Prepared a crisp and concise report with data, analysis and recommendations • Also prepared a regulatory overview document • Captured the potential end users of the product as well as shortlisted potential partners • Offered consulting support for Partnership Development and India Market Entry with a clearly defined Partnering Strategy and roadmap to achieve the goal. • The report helped the University in determining conclusively on India market initiative. • Pleased with the report, the University appointed Aagami to find a licensing partner in India
  25. 25. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Global NPV of Technology (in USD Million) (P) Pessimistic Scenario Discount rate 8.60% Year 2012 2013 2014 2015 2016 2017 2018 Time 0 1 2 3 4 5 6 Revenue from Sale of NPTP POC devices - - 20.30 23.62 32.06 40.80 24.93 Revenue from Sale of Treated Cuvette - - 450.00 614.87 815.48 1,021.15 657.19 Total Cost of NPTP POC devices - - 4.10 5.66 7.69 9.78 5.98 Total Cost of Treated Cuvettes - - 175.00 387.88 514.43 644.17 414.57 Commercialisation Costs 400.00 - - - - - - Total Cash Inflow - - 470.30 638.49 847.54 1,061.96 682.11 Total cash Outflow 400.00 - 179.10 393.54 522.12 653.96 420.55 Net Cash Flow -400.00 - 291.20 244.95 325.43 408.00 261.56 Discount Factor 1.00 0.92 0.85 0.78 0.72 0.66 0.61 Discounted Cash Flow -400.00 - 246.91 191.24 233.96 270.09 159.44 NPV 1,524.77 Assessment of Global Net Present Value (NPV) of a revolutionary Nanotechnology Based Diagnostic Platform • Client wanted to commercialize ground breaking technology in the MI Diagnostics field, and wanted to know its commercial potential so that suitable licensing fees and model could be determined and also value could be showcased to Licensees 25 Investors Controlled Innovative technology company • Aagami involved a team of a senior consultant part time and a business analyst full time to conduct primary and secondary research involving domain specialists to capture current market scenario. • Performed competitive benchmarking to assess a Relative Cost Benefit Index used later for determining technology platform (product) pricing. • Projected annual demand for next ten years in three different scenarios - Median, Optimistic and Pessimistic across multiple disease categories. • Forecasted Global Average Selling Price (ASP) and Cost associated with capex and opex • Validated commercializing options and measured incremental financial scenario for potential licensees • Determined the Global Net Present Value (NPV) and created Financial models • NPV of the technology and indicative licensing fees, along with several insights generated, served as conclusive guidance to the client for deal-making and negotiations. • The client was delighted which also resulted in repeat assignments
  26. 26. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Competitive Landscape Analysis in India to finalize Pricing strategy of high-end Cosmeceuticals • Client, a public limited company in Australia needed to get a competitive landscape of prestige skin whitening, anti-ageing and body shaping market in India, to order to device strategy on their pricing and licensing for Indian Market 26 Publicly Listed Australian skincare products & technology company • Aagami involved a team of a senior and a junior researcher part time to conduct secondary research on web and primary research via in person visits to shops, mall and interviews with Industry professionals, Business owners, store managers, salon managers and doctors to assess market and collect data • Identified Competitors and their product ranges with their Price points and feedback from stakeholders • Prepared a crisp and concise report with data, analysis and Unit Price Map in MS- Excel format in an easy to understand and customized views. • Performed competitive benchmarking to assess a Relative Cost Benefit Index and recommended potential product pricing ranges. • As per client, the report was extremely helpful and enlightening in preparing for their trip to India, and proved essential in determining conclusively whether their product range is capable of selling in the Indian market at the equivalent of Australian retail prices

×